Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Cancer Center of Carolinas/Clinical Research Unit 3rd Floor
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to give informed consent
- Male or female patient whose age is > 18 years of age
- Histological documented Stage IV malignant melanoma (American Joint Committee on Cancer (AJCC) sixth edition)
- Pathology report from tumor specimen verifying melanoma diagnosis
- Free of infection
- Hemoglobin> 9.0 grams per deciliter (gm/dL), White Blood Cells (WBC) >3000/ cubic millimeters (mm3), platelets> 100,000mm3
- Liver function test that are less than 2 times the upper limit of normal of the reference range for the testing laboratory
- Adequate cardiac function-any evidence of ischemic heart disease demonstrated by history, physical, or EKG will require referral to a cardiologist for evaluation and clearance prior to protocol therapy
- No immunotherapy within the past 3 months
- A minimum of 4 doses of lot-released, autologus Melaxin (1.0 million dendritomas)
Exclusion Criteria:
- Other malignancies in the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix
- Has received any immunosuppressive agent within 30 days prior to treat
- Creatinine> 2.5 milligrams per deciliter (mg/dL) or currently on dialysis
- Positive serum pregnancy test, breast-feeding,or planning to conceive or father or father a child in the period surrounding the study as described in the informed consent.
- Women of childbearing potential who cannot follow the directions for birth control
- Eastern Cooperative Oncology Group (ECOG) performance status greater than 3
- Positive Rdonr panel (Human Immunodeficiency virus (HIV) 1, 2; Human T-lymphotropic virus (HTLV-1,2); Hepatitis B and C)
- History of a seizure disorder
- Brain metastases that have progressed within the last 6 months
- No measurable disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Melaxin and BCG
Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG.
The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
|
Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG.
The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety as Measured by Number of Participants With Unexpected Adverse Events or Unexpected Laboratory Results.
Time Frame: From first vaccine to 18 months after the last injection
|
Expected adverse events included injection site reactions, fever, chills, and arthralgias as anticipated with vaccine therapy.
No unexpected or uncommon adverse events occurred such as disseminated sepsis.
Clinical laboratory results on all participants were within expected ranges, including an increase in the number of IFN gamma expressing T-cells.
|
From first vaccine to 18 months after the last injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tumor Response Measured by RECIST Criteria and Progression-free Survival.
Time Frame: From first vaccine to 18 months after the last injection
|
CT scans for disease assessment occurred at three month intervals.
If partial or complete responses were observed confirmation scans were performed within four weeks.
Patients were followed for 18 months post study completion.
All three participants recieved at least one vaccine, and all participants had progression of disease prior to the 18 month followup visit.
|
From first vaccine to 18 months after the last injection
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Thomas E Wagner, PhD, Greenville Hospital System
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CC/ORI 07-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.